English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The additive effect of HC to other agents was first reported in an animal model treated with HC and recombinant erythropoietin (Al-Khatti et al, 1988) and a similar observation was made in SCD patients (Rodgers et al, 1993). Our observation makes the case to incorporate sirolimus, and probably other mTOR inhibitors, in post-transplantation immunosuppressive regimens to prevent rejection in patients with SCD. However, more studies are needed before sirolimus and other mTOR inhibitors can be recommended for SCD patients.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor